This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Thomas G. Pickering, MD, DPhil

JAMA. 1983;249(3):399-400.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Two years ago, when the findings of the Hypertension Detection and Follow-up Program (HDFP) trial of the treatment of patients with mild hypertension were first published,¹ it seemed clear to many persons that there should be no more "benign neglect" in the treatment of such patients whose mortality could be reduced by almost 20% with medication. The HDFP was one of a series of several similar trials, which together present some interesting parallels with the recent secondary prevention trials of β-blockers after myocardial infarction. In both situations, pharmacotherapy is moving from the defensive (relief of symptoms) to the offensive (prevention of morbidity in symptomless persons), and, in both situations, the decision to start a particular individual on treatment depends on a careful weighing of statistical probabilities. Although recommendations have been made for treating all patients who are potentially at risk, there are reasons for taking a more cautious viewpoint, . . . [Full Text PDF of this Article]

Author Affiliations
The New York Hospital—Cornell University Medical Center New York

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?